JP7036792B2 - スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 - Google Patents
スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 Download PDFInfo
- Publication number
- JP7036792B2 JP7036792B2 JP2019505239A JP2019505239A JP7036792B2 JP 7036792 B2 JP7036792 B2 JP 7036792B2 JP 2019505239 A JP2019505239 A JP 2019505239A JP 2019505239 A JP2019505239 A JP 2019505239A JP 7036792 B2 JP7036792 B2 JP 7036792B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- group
- mmol
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CCCCCC(N)=O Chemical compound *CCCCCC(N)=O 0.000 description 6
- IXHFNEAFAWRVCF-UHFFFAOYSA-N CC(C)C(NC)=O Chemical compound CC(C)C(NC)=O IXHFNEAFAWRVCF-UHFFFAOYSA-N 0.000 description 2
- ILCFIPONGKBREU-BYPYZUCNSA-N CNC([C@H](CCC(N)=O)N)=O Chemical compound CNC([C@H](CCC(N)=O)N)=O ILCFIPONGKBREU-BYPYZUCNSA-N 0.000 description 2
- RTRKUCNSVHLDIH-VKHMYHEASA-N CNC([C@H](CS)N)=O Chemical compound CNC([C@H](CS)N)=O RTRKUCNSVHLDIH-VKHMYHEASA-N 0.000 description 2
- NHXXBNOVHYPMHZ-DMTCNVIQSA-N C[C@H]([C@@H](C(NC)=O)N)O Chemical compound C[C@H]([C@@H](C(NC)=O)N)O NHXXBNOVHYPMHZ-DMTCNVIQSA-N 0.000 description 2
- JHLVEBNWCCKSGY-UHFFFAOYSA-N CC(C)(C)OC(NC)=O Chemical compound CC(C)(C)OC(NC)=O JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- PJZBXYKLDPBGFD-VKHMYHEASA-N CNC([C@H](CO)N)=O Chemical compound CNC([C@H](CO)N)=O PJZBXYKLDPBGFD-VKHMYHEASA-N 0.000 description 1
- OOHIGOIEQKKEPK-GSVOUGTGSA-N C[C@H](CC(N)=O)O Chemical compound C[C@H](CC(N)=O)O OOHIGOIEQKKEPK-GSVOUGTGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369465P | 2016-08-01 | 2016-08-01 | |
| US62/369,465 | 2016-08-01 | ||
| US201762523413P | 2017-06-22 | 2017-06-22 | |
| US62/523,413 | 2017-06-22 | ||
| PCT/US2017/044813 WO2018026763A1 (en) | 2016-08-01 | 2017-08-01 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528259A JP2019528259A (ja) | 2019-10-10 |
| JP2019528259A5 JP2019528259A5 (enExample) | 2020-09-17 |
| JP7036792B2 true JP7036792B2 (ja) | 2022-03-15 |
Family
ID=59593189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505239A Active JP7036792B2 (ja) | 2016-08-01 | 2017-08-01 | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10961189B2 (enExample) |
| EP (1) | EP3490974B1 (enExample) |
| JP (1) | JP7036792B2 (enExample) |
| KR (1) | KR102503590B1 (enExample) |
| CN (1) | CN109906218B (enExample) |
| AU (1) | AU2017306136B2 (enExample) |
| BR (1) | BR112019001921A2 (enExample) |
| CA (1) | CA3031534C (enExample) |
| CL (1) | CL2019000246A1 (enExample) |
| CO (1) | CO2019000941A2 (enExample) |
| ES (1) | ES2972533T3 (enExample) |
| IL (1) | IL264488A (enExample) |
| MX (1) | MX385336B (enExample) |
| PE (1) | PE20190500A1 (enExample) |
| PH (1) | PH12019500207A1 (enExample) |
| SG (1) | SG11201900558RA (enExample) |
| WO (1) | WO2018026763A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011003015A (es) | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| CA2898861C (en) | 2013-01-29 | 2021-07-20 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CA3031534C (en) | 2016-08-01 | 2023-10-17 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP2019527235A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
| CN109890825B (zh) | 2016-08-01 | 2022-03-11 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| EP3490992B1 (en) | 2016-08-01 | 2023-03-22 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| CN114685277A (zh) * | 2020-12-31 | 2022-07-01 | 苏州瑞博生物技术股份有限公司 | 化合物及羟基丙酸盐类化合物的纯化方法 |
| CN113956183B (zh) * | 2021-10-28 | 2023-06-20 | 成都市科隆化学品有限公司 | 一种Boc-Ser(Bzl)-OH及其制备方法 |
| WO2024054919A1 (en) * | 2022-09-08 | 2024-03-14 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3360503A (en) * | 1963-04-09 | 1967-12-26 | Du Pont | Process for preparing poly(alpha, alpha-disubstituted beta-lactams) |
| DE2048080C3 (de) * | 1970-09-30 | 1979-11-29 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen |
| EP0180398A1 (en) * | 1984-10-26 | 1986-05-07 | The Regents Of The University Of California | Synthesis of beta-lactam |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
| US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| CA2058223A1 (en) * | 1991-12-20 | 1993-06-21 | Bing-Yan Zhu | Process for preparing beta-lactams |
| FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| NZ332347A (en) | 1996-06-07 | 2000-05-26 | Zeneca Ltd | Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues |
| AU3972797A (en) | 1996-08-02 | 1998-02-25 | Zymogenetics Inc. | Testis-specific insulin homolog polypeptides |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
| WO1999024584A1 (en) | 1997-11-12 | 1999-05-20 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
| WO2000027790A1 (en) | 1998-11-11 | 2000-05-18 | Smithkline Beecham P.L.C. | Mutilin compounds |
| WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
| JP2003521247A (ja) | 2000-02-01 | 2003-07-15 | エージーワイ セラピューティクス インコーポレーテッド | Ｎｍｄａ受容体のプロテインチロシンホスファターゼとの相互作用 |
| JP2001261679A (ja) | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬 |
| WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
| EP1296999A2 (en) | 2000-06-22 | 2003-04-02 | NYXIS NeuroTherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
| GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| WO2002047535A2 (en) | 2000-12-14 | 2002-06-20 | Nyxis Neurotherapies, Inc. | High throughput assay to detect inhibitors of the map kinase pathway |
| US20030065138A1 (en) | 2001-03-07 | 2003-04-03 | University Of Utah Research Foundation | Linear gamma-carboxyglutamate rich conotoxins |
| WO2002072609A2 (en) | 2001-03-12 | 2002-09-19 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| US20030022253A1 (en) | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
| PT1519939E (pt) | 2002-07-05 | 2010-02-10 | Targacept Inc | Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| CA2521625A1 (en) | 2003-04-17 | 2004-11-04 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| EP1776362A1 (en) | 2003-07-18 | 2007-04-25 | Virochem Pharma Inc. | Spiro compounds and methods for the modulation of chemokine receptor activity |
| EP1660634A4 (en) | 2003-08-08 | 2009-02-18 | Burnham Inst | P16-mediated regulation of NMDA receptors |
| US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| WO2005047286A1 (ja) | 2003-11-13 | 2005-05-26 | Ono Pharmaceutical Co., Ltd. | スピロ複素環化合物 |
| ES2359707T3 (es) | 2004-01-08 | 2011-05-26 | F. Hoffmann-La Roche Ag | Derivados de diaza-espiropiperidina. |
| US20060063707A1 (en) | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| CN101090902B (zh) | 2004-10-13 | 2013-05-29 | 默沙东公司 | Cgrp受体拮抗剂 |
| ATE499104T1 (de) | 2005-03-24 | 2011-03-15 | Univ Emory | Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns |
| AU2006282942B2 (en) | 2005-08-26 | 2012-07-26 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
| AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| MX2009002921A (es) | 2006-09-15 | 2009-04-01 | Schering Corp | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. |
| JP2008188285A (ja) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
| MX2009010037A (es) | 2007-03-20 | 2009-11-05 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
| CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
| CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
| US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
| WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
| CA2728727C (en) | 2008-06-24 | 2018-01-23 | Intervet International B.V. | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
| WO2009156396A1 (en) | 2008-06-27 | 2009-12-30 | Neurosearch A/S | Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| EP2323981B1 (en) | 2008-08-07 | 2014-03-12 | F. Hoffmann-La Roche AG | Process for the preparation of a macrocycle |
| GB0814991D0 (en) | 2008-08-15 | 2008-09-24 | Glaxo Group Ltd | Compounds |
| MX2011003015A (es) | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| DE102009001460B4 (de) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | Ölbehälter |
| US8329904B2 (en) | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US20120178695A1 (en) | 2009-07-02 | 2012-07-12 | Joseph Moskal | Methods of treating neuropathic pain |
| EP2485751B1 (en) | 2009-10-05 | 2014-05-21 | Northwestern University | GLYX-13 for use in a method of treating refractory depression |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| WO2011068927A2 (en) | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| US8530648B2 (en) | 2009-12-21 | 2013-09-10 | Novartis Ag | Diaza-spiro[5.5]undecanes |
| SG10201501050RA (en) | 2010-02-11 | 2015-04-29 | Univ Northwestern | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US8097634B2 (en) | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
| CN102267995A (zh) | 2010-06-04 | 2011-12-07 | 艾琪康医药科技（上海）有限公司 | 一种制备二氮杂螺环化合物的方法 |
| WO2012021712A1 (en) | 2010-08-12 | 2012-02-16 | Tetraphase Pharmaceuticals, Inc. | Tetracycline analogs |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| BR112013021638A2 (pt) | 2011-02-25 | 2016-08-02 | Irm Llc | "compostos inibidores de trk, seu uso e composições que os compreendem" |
| AP3339A (en) | 2011-03-14 | 2015-07-31 | Boehringer Ingelheim Int | Benzodioxane inhibitors of leukotriene production |
| KR101309156B1 (ko) * | 2011-03-24 | 2013-09-17 | 삼성에스디아이 주식회사 | 리튬 이차 전지용 전해액 및 이를 포함하는 리튬 이차 전지 |
| MX357761B (es) | 2011-04-27 | 2018-07-23 | Univ Northwestern | Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. |
| CN103635264B (zh) | 2011-06-27 | 2016-06-01 | 皇家飞利浦有限公司 | 超声换能组件及其制造方法 |
| CA2842647A1 (en) | 2011-07-18 | 2013-01-24 | The Governors Of The University Of Alberta | Catalysts and processes for the hydrogenation of amides |
| DK3686193T3 (da) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| US9546179B2 (en) | 2011-12-20 | 2017-01-17 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| CN102936216B (zh) | 2012-12-05 | 2015-03-04 | 南京药石药物研发有限公司 | 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法 |
| CA2898861C (en) | 2013-01-29 | 2021-07-20 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| WO2014120784A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SG11201505937SA (en) | 2013-01-29 | 2015-09-29 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| CN103171641B (zh) | 2013-03-19 | 2015-07-15 | 浙江大学 | 具备轮动功能的弹跳机器人 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| GB2528480A (en) | 2014-07-23 | 2016-01-27 | Givaudan Sa | Improvements in or relating to organic compounds |
| GB201416346D0 (en) | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
| PE20190174A1 (es) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| EP3490992B1 (en) | 2016-08-01 | 2023-03-22 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
| JP2019527235A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| CN109890825B (zh) | 2016-08-01 | 2022-03-11 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| CA3031534C (en) | 2016-08-01 | 2023-10-17 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| JP2021512109A (ja) | 2018-01-31 | 2021-05-13 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
| US20210308101A1 (en) | 2019-11-11 | 2021-10-07 | Aptinyx Inc. | Methods of treating fibromyalgia |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| AU2020398840A1 (en) | 2019-12-04 | 2022-05-26 | Aptinyx Inc. | Methods of treating cognitive impairment associated with neurodegenerative disease |
-
2017
- 2017-08-01 CA CA3031534A patent/CA3031534C/en active Active
- 2017-08-01 JP JP2019505239A patent/JP7036792B2/ja active Active
- 2017-08-01 WO PCT/US2017/044813 patent/WO2018026763A1/en not_active Ceased
- 2017-08-01 EP EP17751911.3A patent/EP3490974B1/en active Active
- 2017-08-01 MX MX2019001318A patent/MX385336B/es unknown
- 2017-08-01 PE PE2019000292A patent/PE20190500A1/es unknown
- 2017-08-01 US US16/321,901 patent/US10961189B2/en active Active
- 2017-08-01 SG SG11201900558RA patent/SG11201900558RA/en unknown
- 2017-08-01 CN CN201780052696.4A patent/CN109906218B/zh active Active
- 2017-08-01 ES ES17751911T patent/ES2972533T3/es active Active
- 2017-08-01 AU AU2017306136A patent/AU2017306136B2/en active Active
- 2017-08-01 KR KR1020197005660A patent/KR102503590B1/ko active Active
- 2017-08-01 BR BR112019001921-9A patent/BR112019001921A2/pt not_active IP Right Cessation
-
2019
- 2019-01-27 IL IL264488A patent/IL264488A/en unknown
- 2019-01-28 PH PH12019500207A patent/PH12019500207A1/en unknown
- 2019-01-30 CO CONC2019/0000941A patent/CO2019000941A2/es unknown
- 2019-01-30 CL CL2019000246A patent/CL2019000246A1/es unknown
-
2021
- 2021-02-17 US US17/177,336 patent/US11512051B2/en active Active
Non-Patent Citations (5)
| Title |
|---|
| Organic & Biomolecular Chemistry，2012年，Vol.10, No.24，pp.4752-4758 |
| REGISTRY（STN）[online]，2003年03月28日，[検索日 2021.05.24], CAS登録番号 500871-61-4 |
| REGISTRY（STN）[online]，2016年03月09日，[検索日 2021.05.24], CAS登録番号 1882390-42-2 など |
| REGISTRY（STN）[online]，2016年04月05日，[検索日 2021.05.24], CAS登録番号 1886984-68-4 |
| Tetrahedron Letters，1990年，Vol.31, No.28，pp.3999-4002 |
Also Published As
| Publication number | Publication date |
|---|---|
| US10961189B2 (en) | 2021-03-30 |
| CL2019000246A1 (es) | 2019-06-21 |
| US20220002242A1 (en) | 2022-01-06 |
| MX385336B (es) | 2025-03-18 |
| EP3490974B1 (en) | 2023-12-06 |
| SG11201900558RA (en) | 2019-02-27 |
| MX2019001318A (es) | 2019-07-01 |
| JP2019528259A (ja) | 2019-10-10 |
| US11512051B2 (en) | 2022-11-29 |
| AU2017306136B2 (en) | 2021-10-21 |
| US20190161442A1 (en) | 2019-05-30 |
| ES2972533T3 (es) | 2024-06-13 |
| CA3031534A1 (en) | 2018-02-08 |
| WO2018026763A1 (en) | 2018-02-08 |
| BR112019001921A2 (pt) | 2019-05-14 |
| KR102503590B1 (ko) | 2023-02-24 |
| AU2017306136A1 (en) | 2019-01-31 |
| CA3031534C (en) | 2023-10-17 |
| CN109906218A (zh) | 2019-06-18 |
| CO2019000941A2 (es) | 2019-02-08 |
| KR20190033593A (ko) | 2019-03-29 |
| PH12019500207A1 (en) | 2019-06-17 |
| PE20190500A1 (es) | 2019-04-10 |
| EP3490974A1 (en) | 2019-06-05 |
| IL264488A (en) | 2019-03-31 |
| CN109906218B (zh) | 2023-01-17 |
| EP3490974C0 (en) | 2023-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7448747B2 (ja) | スピロ－ラクタムｎｍｄａ修飾因子及びこれを用いた方法 | |
| KR102503590B1 (ko) | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 | |
| JP7032378B2 (ja) | スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用 | |
| JP6823083B2 (ja) | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 | |
| JP2019019133A (ja) | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 | |
| JP2021512098A (ja) | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 | |
| KR20150110784A (ko) | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 | |
| CA2899010A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| JP2019527235A (ja) | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200805 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210601 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210603 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210810 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220303 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7036792 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |